Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.06
PTX's Cash to Debt is ranked lower than
55% of the 1176 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. PTX: 0.06 )
PTX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.06

Equity to Asset 0.14
PTX's Equity to Asset is ranked lower than
54% of the 978 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PTX: 0.14 )
PTX' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.99
Current: 0.14

0.06
0.99
F-Score: 3
Z-Score: 0.20
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -25.61
PTX's Operating margin (%) is ranked higher than
52% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. PTX: -25.61 )
PTX' s 10-Year Operating margin (%) Range
Min: -64.4   Max: 38.22
Current: -25.61

-64.4
38.22
Net-margin (%) -36.18
PTX's Net-margin (%) is ranked higher than
50% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. PTX: -36.18 )
PTX' s 10-Year Net-margin (%) Range
Min: -91.07   Max: 33.08
Current: -36.18

-91.07
33.08
ROE (%) -56.90
PTX's ROE (%) is ranked lower than
51% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. PTX: -56.90 )
PTX' s 10-Year ROE (%) Range
Min: -42.27   Max: 137.29
Current: -56.9

-42.27
137.29
ROA (%) -12.71
PTX's ROA (%) is ranked higher than
54% of the 1187 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. PTX: -12.71 )
PTX' s 10-Year ROA (%) Range
Min: -12.35   Max: 68.03
Current: -12.71

-12.35
68.03
ROC (Joel Greenblatt) (%) -269.91
PTX's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1182 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. PTX: -269.91 )
PTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -291.56   Max: 1552.82
Current: -269.91

-291.56
1552.82
Revenue Growth (3Y)(%) 9.00
PTX's Revenue Growth (3Y)(%) is ranked higher than
77% of the 974 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. PTX: 9.00 )
PTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 107
Current: 9

0
107
EBITDA Growth (3Y)(%) -51.90
PTX's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. PTX: -51.90 )
PTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 132.7
Current: -51.9

0
132.7
» PTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PTX Guru Trades in Q2 2014

Jim Simons 157,637 sh (New)
» More
Q3 2014

PTX Guru Trades in Q3 2014

Jim Simons 100,837 sh (-36.03%)
» More
Q4 2014

PTX Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

PTX Guru Trades in Q1 2015

Paul Tudor Jones 49,500 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 6.08
PTX's Forward P/E is ranked higher than
99% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PTX: 6.08 )
N/A
P/B 3.96
PTX's P/B is ranked higher than
67% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. PTX: 3.96 )
PTX' s 10-Year P/B Range
Min: 0.26   Max: 14.61
Current: 3.96

0.26
14.61
P/S 1.78
PTX's P/S is ranked higher than
80% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.31 vs. PTX: 1.78 )
PTX' s 10-Year P/S Range
Min: 0.07   Max: 8.78
Current: 1.78

0.07
8.78
EV-to-EBIT -15.85
PTX's EV-to-EBIT is ranked lower than
59% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.19 vs. PTX: -15.85 )
PTX' s 10-Year EV-to-EBIT Range
Min: -163.1   Max: 280.5
Current: -15.85

-163.1
280.5
Current Ratio 1.21
PTX's Current Ratio is ranked higher than
53% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. PTX: 1.21 )
PTX' s 10-Year Current Ratio Range
Min: 0.84   Max: 64.5
Current: 1.21

0.84
64.5
Quick Ratio 1.08
PTX's Quick Ratio is ranked higher than
60% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. PTX: 1.08 )
PTX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 64.5
Current: 1.08

0.62
64.5
Days Inventory 93.19
PTX's Days Inventory is ranked higher than
81% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. PTX: 93.19 )
PTX' s 10-Year Days Inventory Range
Min: 36.32   Max: 220.74
Current: 93.19

36.32
220.74
Days Sales Outstanding 119.83
PTX's Days Sales Outstanding is ranked higher than
65% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. PTX: 119.83 )
PTX' s 10-Year Days Sales Outstanding Range
Min: 11.14   Max: 208.1
Current: 119.83

11.14
208.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 35.45
PTX's Price/DCF (Projected) is ranked higher than
71% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PTX: 35.45 )
PTX' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 59.39
Current: 35.45

0.28
59.39
Price/Median PS Value 0.96
PTX's Price/Median PS Value is ranked higher than
89% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. PTX: 0.96 )
PTX' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 4.78
Current: 0.96

0.06
4.78
Earnings Yield (Greenblatt) -6.30
PTX's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PTX: -6.30 )
PTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 16.7
Current: -6.3

0.4
16.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:GTAP.Germany,
Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.
» More Articles for NAS:PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Horizon Pharma Up On Bullish Leerink Initiation May 22 2015
5 Stocks Under $10 Set to Soar May 21 2015
Pernix Therapeutics Inc. to Present at Jefferies 2015 Healthcare Conference May 21 2015
Pernix Therapeutics Inc. to Present at Jefferies 2015 Healthcare Conference May 21 2015
Pernix shares jump on migraine drug approval May 15 2015
Pernix shares jump on migraine drug approval May 15 2015
Pernix shares jump on migraine drug approval May 15 2015
Pernix Therapeutics (PTX) Stock Soaring Following FDA Approval of TREXIMET May 15 2015
FDA Approves TREXIMET (sumatriptan and naproxen sodium) for Use in Pediatric Patients May 15 2015
FDA Approves TREXIMET (sumatriptan and naproxen sodium) for Use in Pediatric Patients May 15 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 12 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Financials May 08 2015
4 Biotech Stocks Under $10 to Trade for Breakouts May 07 2015
Pernix Releases Pharmacokinetic Data for ZX007 Third Generation Zohydro ER on Track May 05 2015
Pernix Releases Pharmacokinetic Data for ZX007 May 05 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... May 04 2015
Pernix Launches Zohydro® ER with BeadTek™ May 04 2015
Pernix Launches Zohydro® ER with BeadTek™ May 04 2015
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 01 2015
Pernix Therapeutics Inc. Reports First Quarter 2015 Financial Results May 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK